|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
GlaxoSmithKline |
|---|---|
| Information provided by: | GlaxoSmithKline |
| ClinicalTrials.gov Identifier: | NCT00502775 |
Purpose
The primary objective of the study is to compare nighttime symptom relief of fluticasone furoate nasal spray versus oral fexofenadine
| Condition | Intervention | Phase |
|---|---|---|
|
Allergic Rhinitis Hayfever |
Drug: fluticasone furoate Drug: fexofenadine Drug: placebo |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Parallel Assignment, Efficacy Study |
| Official Title: | A Comparison of Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis |
| Enrollment: | 680 |
| Study Start Date: | August 2007 |
| Study Completion Date: | November 2007 |
| Primary Completion Date: | November 2007 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 12 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion criteria:
Exclusion criteria:
Contacts and Locations
Show 41 Study Locations| Study Director: | GSK Clinical Trials, MD | GlaxoSmithKline |
More Information
| Responsible Party: | GSK ( Study Director ) |
| Study ID Numbers: | FFU109047 |
| Study First Received: | July 17, 2007 |
| Results First Received: | November 17, 2008 |
| Last Updated: | April 3, 2009 |
| ClinicalTrials.gov Identifier: | NCT00502775 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
allergic rhinitis ragweed once daily fluticasone furoate fexofenadine |
|
Anti-Inflammatory Agents Neurotransmitter Agents Otorhinolaryngologic Diseases Anti-Asthmatic Agents Rhinitis Anti-Allergic Agents Histamine Hypersensitivity Histamine Antagonists Respiratory Tract Diseases |
Respiratory Tract Infections Rhinitis, Allergic, Seasonal Fexofenadine Hypersensitivity, Immediate Histamine phosphate Histamine H1 Antagonists Fluticasone Peripheral Nervous System Agents Bronchodilator Agents Respiratory Hypersensitivity |
|
Anti-Inflammatory Agents Respiratory System Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Rhinitis Hypersensitivity Respiratory Tract Infections Respiratory Tract Diseases Therapeutic Uses Fexofenadine Fluticasone Dermatologic Agents Otorhinolaryngologic Diseases Immune System Diseases |
Histamine Agents Anti-Asthmatic Agents Anti-Allergic Agents Nose Diseases Pharmacologic Actions Histamine Antagonists Autonomic Agents Rhinitis, Allergic, Seasonal Hypersensitivity, Immediate Histamine H1 Antagonists Peripheral Nervous System Agents Histamine H1 Antagonists, Non-Sedating Bronchodilator Agents Respiratory Hypersensitivity |